Tirzepatide in a kidney-clinic cohort: association versus causation
A nephrology clinic followed sixty-two adults with chronic kidney disease, diabetes and obesity after tirzepatide was prescribed in routine care.
Human physiology studyPaper year: 2026Tirzepatide
01 / DESIGN
What was studied?
A nephrology clinic followed sixty-two adults with chronic kidney disease, diabetes and obesity after tirzepatide was prescribed in routine care.
02 / FINDINGS
What did the researchers report?
The cohort showed changes in weight, glycemic markers and albuminuria without an observed worsening of kidney function over the reported follow-up.
03 / INTERPRETATION
What are the limits?
There was no randomized comparator. Concurrent care, selection and incomplete follow-up can influence results; the study cannot establish a causal kidney-protection effect.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.
RESEARCH CONTEXT
These are original reading notes on published studies, not product testimonials. Clinical studies used their own pharmaceutical formulations and protocols; their findings do not establish the safety, efficacy or equivalence of materials in our catalog. No personal-use or treatment guidance is provided.
Related catalog navigation only. The supplied material is not established as equivalent to the study product, and the paper does not certify a supply batch.
